Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
If it is I'll be incredibly disappointed, as usual. I hope everyone has asked what's going on with Ox for the Q&A
So three weeks until the agm. Will it be a case of Oxilio talks still ongoing I wonder.
ATM
Well thats one out of the way with no knock on the price, 313,020.
Just need news to come our way.
Traders try to find their way out today. Pretty much all at a loss.
Good to see it hang on despite yesterdays 500k seller being desperate to exit. Its good when the MM's won't take their shares.
Everyone else who bought yesterdays rise will now face the fact they need to hold on as they can't sell at a profit. Only 8 trades from yesterday were below the current sell price, and they've all been sold.
Traders being made to sweat.
Anne's announcement was overdone in imho .
Slowly it will creep back ,your got ox short term to come,
Anybody taking a stake now will be in pocket, ,how much is only a guess.
Same old BS. In a few days time we'll probably see the rest of todays entrants panic and dump and they'll drag the price down even further.
This mornings 500k buyer is trying to exit for a couple of hundred quid now.
Well whoever just sold 196k didn't have much patience, they only held them from an hour and a half.
Pump & dump most likely, dog of a company, uninvestable. Bid already dropping back down on this POS.
Indeed, just happy to have a day with some sort of positive price action no matter what its based on.
Don't want to temp fate but where are our usual sellers? If we can start to recover towards 3p now I'd be a very happy boy
Nice buys today, hope it continues
"The licensing discussions with Oxilio for NXP001 are ongoing and further news on this will be announced via RNS as soon as it is available. "
What Oxillio rns are you expecting?
Hoping for something before AGM but not getting hopes up at all. Part time nature of this company shining through at the moment, Nuformix should've been Anne's No 1 priority but doubting this, if it is tell us
Yawn
Morning boys and girls. Anybody out there?
No Ox rns, but if and when it does come let's please get FULL disclosure.
ATB
licensing agreement with AstraZeneca worth a headline US$377mln and upfront milestone; and another preclinical licensing agreement with Abbvie and Morphic Therapeutics was also done with an undisclosed headline value, again with upfront milestones.
In NXP002, Nuformix has eschewed traditional drug development by creating a new form of the original drug, tranilast, which has a long history of safe use as an oral drug for allergies in Asia but with evidence that supports its potential in fibrosis, including IPF.
Nuformix has generated its own IP, repurposing an existing drug and giving it a potential new lease of life with significant commercial potential.
NXP002 is differentiated because it's a new form of tranilast and it will be formulated for delivery direct to the lungs by inhalation, a new route of administration for this drug.
There are two reasons why this change in route of administration is important.
The first is practical as it provides a targeted treatment with hopefully fewer side-effects.
The second is that by discovering novel forms of tranilast, Nuformix is able to generate IP and get patent protection from generics.
IPF itself is an area of high unmet medical need and an ‘orphan’ disease. It’s a severe and progressive disease that affects the lungs, where dust, smoke, gastric reflux acid, genetic predisposition or infection leads to scarring known as fibrosis.
The prognosis is as bleak as some aggressive forms of cancer with an average survival time of three to five years.
While there are treatments, they tend only to be partially effective and have significant side-effects that cause some patients to stop treatment.
Because of the rarity of the disease, any new drugs that show signs of potential efficacy are likely to receive orphan drug designation.
This regulatory classification expedites the clinical trial process, reduces costs and extends the exclusivity period of the end product.
Taking the re-purposing route with Tranilast, rather than developing and testing a totally new molecule, compound or cell therapy, may also help shorten the timeline to market.
For example, a lot is already known about the safety and the way a drug such as Tranilast interacts with the body.
So, in this regard, there is also a greater probability of success, while the development costs are likely also to be lower than they would be with an unknown new therapy.
Utilising a technology known as cocrystallisation, Nuformix re-engineers a drug’s crystalline form by adding a molecule that improves it in a variety of ways – how well it can be absorbed by the body, for example.
Drug repurposing is a well-known strategy for enhancing the therapeutic and commercial value of marketed drugs:
• Greater probability of success compared to developing new drugs, due to the existing data, particularly safety, already generated on the marketed drug.
• Existence of data may also result in lower overall development costs and shorter development timelines.
• Commercial potential of these drugs may be enhanced by differentiation by way of formulation, route of administration or dose and gaining patent protection.
We aim to use our expertise in solid form science to discover and file patent applications on new solid forms to facilitate development of alternative formulations and delivery methods to repurpose marketed drugs into differentiated products for new indications.
Nuformix looks for three things in candidates suitable for their approach to reprofiling.
“Is the drug safe, does it have a problem our tech can improve and is there an underlying therapeutically innovative pharmacology with some level of validation in an area of unmet medical need.”
For example, using cocrystal technology can change key drug properties, such as solubility or dissolution rate, without changing the chemistry inside.
That means a drug can dissolve faster and to a greater extent so more of the drug gets into the patient, though solubility is just one of many problems an existing drug might face.
“Many properties hold drugs back from doing other things, but in certain cases we have an opportunity to change that.
“When we discover new drug cocrystals, we can patent these new substances and leverage their improved properties in new and unique products.”
“Every drug cocrystal we discover, we breathe a new 20-year lifespan into products enabled by that substance.”
Drug reprofiling
Switching disease use is called drug reprofiling and means rather than starting from scratch when designing a new therapy, you take a treatment for disease A and reprofile it to treat disease B.
Because known drugs have usually been approved previously and their underlying chemistry is not changing, safety issues have been addressed, removing a major hurdle in drug development.
That leaves Nuformix just to prove that the new application passes muster against existing standard of care treatments.
“We take our cocrystal-based products through development to proof-of-concept stage before seeking to out-license to a marketing partner,”
There has been a spate of preclinical deals, not least by the UK’s C4X Discovery, which has landed two separate partnerships – one with Indivior the other with Sanofi – worth a combined £580mln in upfront, milestone and royalty payments. More relevant and in the area of fibrosis (IPF), AIM-listed Redx Pharma inked a